CEO Executive AssistantChemistry, manufacturing, and controls operations represent one of the most technically specialized and operationally complex functions in the pharmaceutical and biotech organization. CMC encompasses the development, scale-up, validation, regulatory submission, and commercial production of pharmaceutical drug substances and drug products, along with the analytical methods and quality systems that ensure product quality and patient safety.
For pharmaceutical and biotech CEOs, CMC presents a distinctive delegation challenge. The technical complexity is high enough that most CEOs lack deep personal expertise to evaluate CMC decisions independently. Yet the stakes, product quality, manufacturing reliability, regulatory approval, and supply continuity, are among the highest in the organization. Getting the delegation model right for CMC requires building the right leadership, governance, and oversight mechanisms rather than attempting personal operational management.
This guide gives pharma and biotech CEOs a practical framework for delegating CMC operations while maintaining the strategic oversight that quality and regulatory compliance require.
Why CMC Deserves CEO Strategic Attention
CMC is not simply an operational function. It is a source of strategic risk and competitive advantage that the CEO must understand and actively govern.
Regulatory approval dependency. The FDA and other regulatory authorities will not approve a drug without satisfactory CMC data demonstrating product quality, manufacturing process control, and analytical method validation. CMC deficiencies are a leading cause of regulatory delays and approval rejections.
Supply chain risk. Manufacturing problems, supply disruptions, and quality failures can interrupt the supply of approved products, creating patient safety risks, revenue losses, and regulatory consequences. Managing this supply risk requires strategic organizational attention.
Cost structure implications. Manufacturing costs are a major component of pharmaceutical economics, particularly for biologics and complex drug products. Investment in manufacturing infrastructure, process optimization, and quality systems has direct implications for the company’s cost structure and competitive position.
CMC as partnership asset. For companies seeking co-development or licensing partners, the quality of CMC capabilities is a significant due diligence criterion. Strong CMC infrastructure and a clean regulatory history attract better partners and better terms.
The CEO’s CMC Governance Role
The CEO’s role in CMC is governance rather than operations: ensuring that the function has appropriate leadership, resources, and oversight mechanisms, and engaging personally when CMC issues rise to the level of strategic organizational risk.
Resource allocation and investment decisions. Capital investment in manufacturing infrastructure, decisions about building versus outsourcing manufacturing capacity, and CMC budget allocation across programs all require CEO-level judgment about strategic priorities and financial commitments.
CMO and manufacturing leadership management. The VP of manufacturing, head of CMC, or COO who owns the manufacturing function should be a direct report or close partner to the CEO. Managing this relationship, setting expectations, reviewing performance, and holding manufacturing leadership accountable for quality and supply performance are CEO functions.
Major quality or supply failures. When a significant manufacturing quality failure, a product recall, or a supply disruption threatens patient safety or organizational reputation, the CEO must lead the organizational response. This includes engaging with the FDA, communicating with partners and customers, and making decisions about remediation investments.
Regulatory submission strategy for CMC. Major CMC regulatory submissions, including NDA and BLA filings, require CEO awareness of the regulatory timeline and CEO engagement when CMC issues affect the overall regulatory strategy.
Delegating CMC Operations
Below the CEO’s governance role, CMC operations are managed by a dedicated functional leadership team.
VP of Manufacturing or Head of CMC. This leader owns the full CMC function: drug substance and drug product manufacturing, process development, scale-up and technology transfer, analytical development, quality control, and supply chain management. The CEO sets strategic direction and performance expectations; the head of CMC manages the function.
Quality organization. A VP of quality or head of quality assurance should own the quality management system: GMP compliance, quality control laboratory operations, quality auditing, regulatory agency interactions related to quality, and product release decisions. Quality functions must have organizational independence to make quality decisions without commercial pressure.
Regulatory CMC team. CMC regulatory specialists should own the regulatory submissions and agency interactions related to manufacturing: preparing CMC sections of regulatory submissions, managing responses to FDA manufacturing questions, and coordinating CMC strategy with regulatory affairs.
Supply chain function. A supply chain director or VP of supply chain should own raw material procurement, CMO management, supply planning, inventory management, and distribution logistics. For companies that manufacture their own products, this function works in close partnership with manufacturing operations.
Process development team. A process development director should own the development and optimization of manufacturing processes: cell line development for biologics, formulation development, analytical method development, and process scale-up studies.
For a broader framework on how pharma and biotech CEOs delegate across the organization, see our resource on pharma CEO guide.
CMC Risk Management and CEO Oversight
Effective delegation of CMC operations requires robust risk management and reporting mechanisms that give the CEO visibility into significant CMC risks without requiring direct operational involvement.
A CMC risk dashboard, reviewed by the CEO quarterly and presented to the board annually, should summarize: manufacturing quality metrics including batch failure rates and deviation trends, supply chain risk indicators including raw material availability and CMO performance, regulatory CMC submission status and any open deficiencies, and forward-looking supply projections against demand forecasts.
When the CMC risk dashboard identifies significant concerns, the CEO engages with the CMC leadership team to understand the issues and resource decisions needed to address them. This risk-based engagement model gives the CEO appropriate oversight without requiring immersion in CMC operational detail.
Managing Contract Manufacturing Organizations
Many pharmaceutical companies rely on CMOs for some or all of their manufacturing. Managing CMO relationships is a significant operational function with strategic implications.
The supply chain and manufacturing teams should own CMO relationship management: managing contracts, conducting performance reviews, overseeing technology transfers, managing quality audits, and addressing performance concerns. The CEO engages when a CMO relationship involves major financial commitments, when a CMO quality failure creates strategic risk, or when selecting a CMO for a program of strategic significance.
A CMO governance framework that defines relationship responsibilities, performance expectations, and escalation protocols gives the supply chain and manufacturing teams the structure needed to manage CMO relationships effectively without constant CEO involvement.
Quality Culture and CEO Leadership
Quality in pharmaceutical manufacturing is ultimately a cultural question as much as a technical one. Manufacturing teams that are genuinely committed to quality, where concerns are raised proactively and problems are resolved transparently rather than hidden, produce better outcomes than those where quality is treated as a compliance obligation rather than a professional commitment.
The CEO cannot delegate quality culture. Setting the organizational tone on quality requires visible CEO leadership: celebrating quality achievements, investigating quality failures with curiosity rather than blame, investing in quality systems even when resources are tight, and treating patient safety as a non-negotiable organizational value.
The operational quality management systems and compliance programs are owned by the quality function. The culture that gives them their meaning is set by the CEO.
CMC in Business Development and Partnerships
When pharmaceutical companies are involved in business development activities, CMC capability is often a critical due diligence consideration. Potential partners will evaluate manufacturing capabilities, quality track record, regulatory history, and supply reliability before committing to a co-development or licensing agreement.
The CEO should ensure that the CMC function is prepared to support business development activities: maintaining clear documentation of manufacturing capabilities, sustaining a clean regulatory history, and addressing quality or compliance issues that might affect partnership attractiveness.
The CMC team should be engaged early in business development processes that will involve CMC due diligence, so that they can prepare materials, anticipate questions, and address concerns before they become deal-breakers.
Capital Investment Decisions in Manufacturing
Pharmaceutical manufacturing requires significant capital investment in facilities, equipment, and technology. Decisions about manufacturing capital investment are strategic CEO decisions with major financial implications.
The manufacturing and finance teams should prepare analysis that supports major capital investment decisions: manufacturing capacity needs, build versus buy versus outsource analysis, capital cost estimates, and return on investment modeling. The CEO makes the final decision about major capital commitments, informed by this analysis.
Routine capital maintenance, equipment upgrades within established budgets, and minor facility improvements can be approved by the head of manufacturing within established delegated financial authority levels.
Regulatory CMC Interactions
FDA interactions related to CMC, including pre-submission meetings, responses to manufacturing questions, and facility inspections, require close coordination between the regulatory affairs team and the CMC organization.
A joint regulatory-CMC team should manage the operational dimensions of FDA CMC interactions: preparing meeting briefing books, drafting responses to FDA requests, coordinating pre-approval inspection readiness, and managing post-inspection response activities.
The CEO engages when significant CMC regulatory issues threaten the overall program regulatory timeline or when CEO-to-FDA-leadership communication is needed to address a significant concern.
According to McKinsey and Company, pharmaceutical companies that invest in manufacturing excellence as a strategic priority, with strong senior leadership commitment and dedicated organizational capability, achieve consistently better regulatory outcomes and supply performance than those that treat manufacturing as a purely operational function.
Succession and Knowledge Management in CMC
CMC knowledge is highly specialized and can be difficult to replace when key personnel leave. Building knowledge management practices into the CMC organization reduces the dependency on specific individuals and makes delegation more resilient.
Process documentation, manufacturing batch records, analytical method development files, and regulatory submission archives should be maintained in systems that are accessible to the team rather than residing primarily with individuals. Cross-training programs, knowledge transfer processes, and structured onboarding for CMC staff build organizational resilience.
The CEO should champion investment in CMC knowledge management as part of the broader organizational risk management function, even though the operational implementation belongs with CMC leadership.
The CEO’s CMC Investment Philosophy
The pharmaceutical CEO who views CMC as a strategic function deserving investment and senior leadership attention, rather than as an operational cost center to be minimized, builds a significantly more competitive and resilient organization.
Manufacturing quality, supply reliability, and regulatory CMC credibility are competitive advantages that are genuinely difficult to build quickly. CEOs who invest in these capabilities consistently, even before they face a manufacturing crisis that makes the investment obviously necessary, are making one of the highest-return strategic investments available to them.
For guidance on delegating the drug pipeline management that depends on CMC capabilities, see our resource on pharma drug pipeline.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.